1. •• Fokkens W, Lund V, Hopkins HP, Kern R, Reitsma S, et al. EPOS2020: European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464 The 2020 Updated European position paper on Rhinosinusitis and nasal polyps is performing an extended up-to-date, a clear evidence-based recommendations and integrated care pathways in ARS and CRS. It has been the basis for this review article.
2. •• Stjärne P, Odebäck P, Ställberg B, Lundberg J, Olsson P. High costs and burden of illness in acute rhinosinusitis: real-life treatment patterns and outcomes in Swedish primary care. Primary Care Resp Journal. 2012;21:174–9 It is the first study on the ARS costs in Europe. Total cost for an ARS episode was 10,260 SEK (€1,102), 755 of which was related to indirect costs.
3. • Jaume F, Quintó L, Alobid I, Mullol J. Overuse of diagnostic tools and medications in acute rhinosinusitis in Spain: a population-based study (the PROSINUS study). BMJ Open. 2018;8(1):e018788 By excluding bacterial ARS, this article shows a significant abuse of diagnostic tools and overuse of medications, predominantly oral antibiotics, by PCPs and ORLs, for both viral and postviral ARS, in Spain.
4. •• Orlandi RR, Kingdom TT, Hwang PH, Smith TL, Alt JA, Baroody FM, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(Suppl 1):S22–S209 This international guideline, mainly from American authors, also reviewed the literature on acute and chronic rhinosinuistis topics, providing evidence-based recommendations for medical and surgical treatment.
5. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:1–298.